ArticleMelanoma research2013
Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.
Article in Melanoma research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Clinical outcomes of intrathecal anti-PD-1 therapy with or without whole-brain radiotherapy in melanoma leptomeningeal metastasis: a multicenter retrospective study.Frontiers in immunology · 2026Article
- Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.Acta neuropathologica communications · 2024Article
- Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.Neuro-oncology practice · 2024Article
- A case report and literature review on primary intracranial malignant melanoma: Challenges and insights.International journal of surgery case reports · 2024Article
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Pigment cell & melanoma research · 2024Review
- Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.Current treatment options in oncology · 2023Review
- Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape.Current oncology (Toronto, Ont.) · 2023Review
- Review
- Review
- Leptomeningeal Metastases: New Opportunities in the Modern Era.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.Current oncology reports · 2022Review
- Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches.Cancers · 2021Review
- Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.Immunotherapy · 2020Article
- Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.Pigment cell & melanoma research · 2020Review
- Targeted Therapy After Brain Radiotherapy for BRAF-Mutated Melanoma With Extensive Ependymal Disease With Prolonged Survival: Case Report and Review of the Literature.Frontiers in oncology · 2019Article
- Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.American journal of clinical dermatology · 2018Review
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.Scientific reports · 2018Article
- Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.The oncologist · 2017Article
- Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.Ochsner journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
We present a patient with metastatic BRAF-mutated melanoma who achieved long-term stabilization of leptomeningeal disease (LMD) with sequential whole-brain radiation therapy and vemurafenib. A 53-year-old woman with melanoma that harbored the BRAF V600E mutation and had that metastasized to multiple lymph nodes, lungs, breast, and subcutaneous tissue had developed symptomatic LMD 16 months after starting vemurafenib treatment despite achieving a substantial response at the existing metastatic sites. Vemurafenib was discontinued for 7 days, she received whole-brain radiation therapy (30 Gy in 10 fractions), and 7 days after completing the radiation therapy, she resumed vemurafenib therapy. The neurologic symptoms improved significantly, and a cerebrospinal fluid examination revealed disappearance of melanoma cells. She remained alive with radiologically stable LMD for at least 18 months after the whole-brain radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.